Free Trial
NASDAQ:INBX

Inhibrx Biosciences (INBX) Stock Price, News & Analysis

Inhibrx Biosciences logo
$83.30 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$80.39 -2.91 (-3.50%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Inhibrx Biosciences Stock (NASDAQ:INBX)

Advanced

Key Stats

Today's Range
$80.68
▼
$87.91
50-Day Range
$71.78
▼
$121.17
52-Week Range
$57.30
▼
$155.29
Volume
245,896 shs
Average Volume
303,291 shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$197.50
Consensus Rating
Moderate Buy

Company Overview

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body.

The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Inhibrx Biosciences emerged in 2024 from the restructuring of its former parent, Inhibrx, Inc., following Sanofi’s acquisition of certain Inhibrx assets. The company retained a portfolio of development programs, with its work centered on advancing investigational biologics through clinical development.

AI Generated. May Contain Errors.

Inhibrx Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

INBX MarketRank™: 
3.393473069775 of 5 stars

Inhibrx Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 251st out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inhibrx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 2 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Inhibrx Biosciences has a consensus price target of $197.50, representing about 137.1% upside from its current price of $83.30.

  • Amount of Analyst Coverage

    Inhibrx Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Inhibrx Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Inhibrx Biosciences are expected to grow in the coming year, from ($9.91) to ($9.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inhibrx Biosciences is -9.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inhibrx Biosciences is -9.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inhibrx Biosciences has a P/B Ratio of 151.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    28.17% of the float of Inhibrx Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibrx Biosciences has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibrx Biosciences has recently decreased by 0.82%, indicating that investor sentiment is improving.
  • Dividend Yield

    Inhibrx Biosciences does not currently pay a dividend.

  • Dividend Growth

    Inhibrx Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Inhibrx Biosciences has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Inhibrx Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Inhibrx Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Cluster Insider Buying

    3 insiders have purchased shares of Inhibrx Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $6,178,917.00 in company stock, which represents 0.5040% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Inhibrx Biosciences insiders have bought 3,665.06% more of their company's stock than they have sold. Specifically, they have bought $6,347,507.00 in company stock and sold $168,590.00 in company stock.

  • Percentage Held by Insiders

    18.26% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Inhibrx Biosciences' insider trading history.
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INBX Stock News Headlines

Inhibrx Q3 Loss Widens
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Earnings Flash (INBX) Inhibrx Biosciences, Inc. Reports Q3 Revenue $2.0M
Inhibrx Reports Third Quarter 2026 Financial Results
See More Headlines

INBX Stock Analysis - Frequently Asked Questions

Inhibrx Biosciences' stock was trading at $79.00 at the beginning of the year. Since then, INBX stock has increased by 5.4% and is now trading at $83.30.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced its quarterly earnings data on Friday, November, 13th. The company reported ($2.46) EPS for the quarter, missing the consensus estimate of ($2.45) by $0.01. The firm earned $2 million during the quarter, compared to the consensus estimate of $1.90 million.

Inhibrx Biosciences (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Inhibrx Biosciences' top institutional shareholders include HighTower Advisors LLC (6.01%), State Street Corp (3.84%), First Trust Advisors LP (0.86%) and Healthcare of Ontario Pension Plan Trust Fund (0.66%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Jon Faiz Kayyem, Douglas Forsyth, Global Investors Lp Viking, Kimberly Manhard and Kristiina Md Vuori.
View institutional ownership trends
.

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include CRISPR Therapeutics (CRSP), CrowdStrike (CRWD), Plug Power (PLUG), Quantum Computing (QUBT), Red Cat (RCAT), Shoals Technologies Group (SHLS) and USA Rare Earth (USAR).

Company Calendar

Last Earnings
11/13/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INBX
CIK
2007919
Fax
N/A
Employees
110
Year Founded
2017

Price Target and Rating

High Price Target
$245.00
Low Price Target
$150.00
Potential Upside/Downside
+137.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($9.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$140.05 million
Net Margins
N/A
Pretax Margin
-10,014.08%
Return on Equity
-563.90%
Return on Assets
-87.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.07
Quick Ratio
5.07

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.55 per share
Price / Book
151.45

Miscellaneous

Outstanding Shares
14,718,000
Free Float
12,030,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
4.03

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:INBX) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners